Regentatlantic Capital Upped By $811,725 Its United Contl Hldgs (UAL) Stake; 8 Analysts Are Bullish Inovio Pharmaceuticals (INO) Last Week

November 8, 2017 - By Hazel Jackson

Regentatlantic Capital Llc increased United Contl Hldgs Inc (UAL) stake by 42.8% reported in 2017Q2 SEC filing. Regentatlantic Capital Llc acquired 10,823 shares as United Contl Hldgs Inc (UAL)’s stock rose 2.66%. The Regentatlantic Capital Llc holds 36,110 shares with $2.72 million value, up from 25,287 last quarter. United Contl Hldgs Inc now has $17.39 billion valuation. It closed at $58.71 lastly. It is down 77.19% since November 8, 2016 and is uptrending. It has outperformed by 60.49% the S&P500.

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals had 32 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Inovio Pharmaceuticals Inc (NASDAQ:INO) earned “Buy” rating by Stifel Nicolaus on Tuesday, August 8. The stock of Inovio Pharmaceuticals Inc (NASDAQ:INO) earned “Neutral” rating by PiperJaffray on Thursday, March 16. The rating was maintained by Aegis Capital with “Buy” on Thursday, June 8. The company was maintained on Monday, June 26 by Stifel Nicolaus. H.C. Wainwright maintained the shares of INO in report on Friday, September 22 with “Buy” rating. On Tuesday, September 12 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating given on Thursday, June 1 by Aegis Capital. The rating was maintained by Brean Capital with “Buy” on Monday, March 14. The firm earned “Hold” rating on Tuesday, August 9 by Maxim Group. As per Tuesday, January 5, the company rating was maintained by Maxim Group. See Inovio Pharmaceuticals Inc (NASDAQ:INO) latest ratings:

25/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
18/10/2017 Broker: RBC Capital Markets Rating: Outperform New Target: $11 Initiates Coverage On
17/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
05/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $11.0 Maintain
06/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
06/10/2017 Broker: Citigroup Rating: Buy New Target: $10.0 Initiate
22/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
12/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $13.0 Maintain
06/09/2017 Broker: Citigroup Rating: Buy New Target: $10.0 Initiate
08/08/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $11.0000 Maintain

Regentatlantic Capital Llc decreased Unitedhealth Group Inc (NYSE:UNH) stake by 1,636 shares to 76,035 valued at $14.10 million in 2017Q2. It also reduced Microsoft Corp (NASDAQ:MSFT) stake by 6,602 shares and now owns 191,933 shares. Spdr Index Shs Fds (GWX) was reduced too.

Among 23 analysts covering United Continental (NYSE:UAL), 7 have Buy rating, 2 Sell and 14 Hold. Therefore 30% are positive. United Continental had 76 analyst reports since July 24, 2015 according to SRatingsIntel. Morgan Stanley maintained United Continental Holdings Inc (NYSE:UAL) rating on Thursday, April 28. Morgan Stanley has “Overweight” rating and $58 target. Barclays Capital initiated United Continental Holdings Inc (NYSE:UAL) on Thursday, December 15 with “Overweight” rating. The firm has “Outperform” rating given on Friday, March 17 by Imperial Capital. Bank of America upgraded the shares of UAL in report on Thursday, June 29 to “Buy” rating. The firm has “Market Perform” rating given on Thursday, March 24 by Raymond James. Cowen & Co maintained the shares of UAL in report on Wednesday, November 16 with “Outperform” rating. Stifel Nicolaus maintained it with “Buy” rating and $110.0 target in Wednesday, September 20 report. As per Friday, January 22, the company rating was maintained by Credit Suisse. Imperial Capital initiated United Continental Holdings Inc (NYSE:UAL) rating on Tuesday, August 23. Imperial Capital has “Outperform” rating and $57 target. The stock of United Continental Holdings Inc (NYSE:UAL) has “Outperform” rating given on Wednesday, October 12 by Imperial Capital.

Since May 9, 2017, it had 0 insider purchases, and 1 insider sale for $230,504 activity. $786,342 worth of United Continental Holdings Inc (NYSE:UAL) was sold by Bonds Michael P on Tuesday, May 9. $230,504 worth of United Continental Holdings Inc (NYSE:UAL) was sold by Hart Gregory L on Wednesday, June 14.

Investors sentiment decreased to 0.79 in 2017 Q2. Its down 0.12, from 0.91 in 2017Q1. It is negative, as 49 investors sold UAL shares while 222 reduced holdings. 73 funds opened positions while 141 raised stakes. 279.97 million shares or 4.99% less from 294.67 million shares in 2017Q1 were reported. Nebraska-based Nelson Van Denburg & Campbell Wealth Management Group Ltd Liability has invested 0% in United Continental Holdings Inc (NYSE:UAL). Shellback Cap Lp holds 248,462 shares. Tocqueville Asset Mgmt Limited Partnership stated it has 13,263 shares or 0.01% of all its holdings. Denali Advsrs Ltd Llc owns 134,300 shares or 1.65% of their US portfolio. Glendon Mgmt LP stated it has 63,346 shares or 1.22% of all its holdings. Tower Research Cap Limited Liability Company (Trc) invested in 4,176 shares. Nuveen Asset Management Ltd Company has 0.13% invested in United Continental Holdings Inc (NYSE:UAL). Hanson Mcclain Inc reported 67 shares. Magnetar Financial Lc owns 0.03% invested in United Continental Holdings Inc (NYSE:UAL) for 24,611 shares. 421,208 were reported by Robeco Institutional Asset Bv. Westwood Mgmt Il owns 4.4% invested in United Continental Holdings Inc (NYSE:UAL) for 373,500 shares. Los Angeles Capital Mgmt & Equity Rech reported 238,227 shares or 0.11% of all its holdings. Raymond James Fincl Svcs Inc reported 5,889 shares stake. Andra Ap reported 32,200 shares or 0.06% of all its holdings. 80,000 were reported by Rbf Limited Liability Company.

It closed at $5.31 lastly. It is down 29.01% since November 8, 2016 and is downtrending. It has underperformed by 45.71% the S&P500.

Inovio Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The company has market cap of $479.11 million. The Company’s DNA immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It currently has negative earnings. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus.